ImmuCell Corporation (ICCC)

ImmuCell Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	0.98	5.79	10.19	6.95	6.29
Short-Term Investments	0	0	0	1	2.48
Cash & Cash Equivalents	0.98	5.79	10.19	7.95	8.77
Cash Growth	-83.10%	-43.14%	28.18%	-9.43%	248.03%
Receivables	2.19	1.76	2.69	1.8	1.64
Inventory	7.81	6.04	3.09	2.09	2.52
Other Current Assets	0.49	0.41	0.3	0.32	0.26
Total Current Assets	11.47	13.99	16.26	12.16	13.19
Property, Plant & Equipment	32.15	30.64	28	27.98	25.27
Goodwill and Intangibles	0.13	0.15	0.17	0.19	0.21
Other Long-Term Assets	0.06	0.08	0.03	0.03	0.03
Total Long-Term Assets	32.34	30.87	28.2	28.19	25.5
Total Assets	43.81	44.86	44.47	40.35	38.69
Accounts Payable	2.12	2	1.61	1.35	1.22
Current Debt	2.07	1.07	0.92	0.86	1.27
Total Current Liabilities	4.2	3.07	2.53	2.21	2.5
Long-Term Debt	14.62	11.41	9.35	9.87	7.15
Other Long-Term Liabilities	0	0	0	0	0.06
Total Long-Term Liabilities	14.62	11.41	9.35	9.87	7.21
Total Liabilities	18.82	14.48	11.89	12.08	9.7
Total Debt	16.69	12.48	10.27	10.73	8.42
Debt Growth	33.74%	21.46%	-4.27%	27.45%	-13.77%
Retained Earnings	-12.01	-6.23	-3.74	-3.66	-2.64
Comprehensive Income	0	0	0	0	-0.04
Shareholders' Equity	24.99	30.38	32.58	28.27	28.99
Net Cash / Debt	-15.71	-6.69	-0.09	-2.79	0.35
Net Cash Per Share	-2.03	-0.86	-0.01	-0.39	0.05
Working Capital	7.27	10.92	13.73	9.95	10.69
Book Value Per Share	3.23	3.92	4.29	3.92	4.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).